(Q34980292)

5 August 2017

A novel five-antibody immunohistochemical test for subclassification of lung carcinoma (English)

1 reference

5 August 2017

1 reference

1 reference

9

Douglas T Ross

1 reference

5 August 2017

Brian Z Ring

1

1 reference

5 August 2017

Robert S Seitz

2

1 reference

5 August 2017

Rodney A Beck

3

1 reference

5 August 2017

William J Shasteen

4

1 reference

5 August 2017

Alex Soltermann

5

1 reference

5 August 2017

Stefanie Arbogast

6

1 reference

5 August 2017

Francisco Robert

7

1 reference

5 August 2017

Marshall T Schreeder

8

1 reference

5 August 2017

8 May 2009

1 reference

5 August 2017

1 reference

5 August 2017

22

1 reference

5 August 2017

1032-1043

1 reference

5 August 2017

8

1 reference

https://scigraph.springernature.com/pub.10.1038/modpathol.2009.60

5 August 2017

0 references

cites work

The 2004 World Health Organization classification of lung tumors

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

A five-gene signature and clinical outcome in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

Diversity of gene expression in adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

Predicting survival within the lung cancer histopathological hierarchy using a multi-scale genomic model of development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

A gene expression signature predicts survival of patients with stage I non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

Molecular classification and molecular genetics of human lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

New molecularly targeted therapies for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

Histotype in Non-Small Cell Lung Cancer Therapy and Staging: The Emerging Role of an Old and Underrated Factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

Cytology applications of p63 and TTF-1 immunostaining in differential diagnosis of lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

P63 expression in lung carcinoma: a tissue microarray study of 408 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

Molecular and functional identification of large neutral amino acid transporters LAT1 and LAT2 and their pharmacological relevance at the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

Accurate discrimination of pancreatic ductal adenocarcinoma and chronic pancreatitis using multimarker expression data and samples obtained by minimally invasive fine needle aspiration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

The new World Health Organization classification of lung tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

Basal cell (basaloid) carcinoma of the lung: a new morphologic and phenotypic entity with separate prognostic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

inferred from DOI database lookup

7 January 2021

based on heuristic

The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.60

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/MODPATHOL.2009.60

1 reference

Dimensions Publication ID

5 August 2017

0 references

1 reference